Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC has increased its stake in Kiniksa Pharmaceuticals International by 149.1%, owning approximately $10.92 million in KNSA shares as of the end of the first quarter.
• Several institutional investors have significantly modified their holdings, with Deutsche Bank AG increasing its position by 177.1%, now owning shares valued at $8.76 million.
• Kiniksa Pharmaceuticals announced strong quarterly earnings, reporting $0.23 EPS, surpassing estimates and achieving revenue of $156.8 million during the last quarter.

AQR Capital Management LLC raised its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 149.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 491,761 shares of the company's stock after purchasing an additional 294,319 shares during the quarter. AQR Capital Management LLC owned 0.67% of Kiniksa Pharmaceuticals International worth $10,922,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Kiniksa Pharmaceuticals International by 23.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock worth $299,000 after acquiring an additional 2,881 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Kiniksa Pharmaceuticals International by 11.1% during the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after acquiring an additional 28,393 shares in the last quarter. Bank of America Corp DE lifted its stake in Kiniksa Pharmaceuticals International by 2.2% in the 4th quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock valued at $4,268,000 after buying an additional 4,654 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $256,000. Finally, Deutsche Bank AG lifted its stake in Kiniksa Pharmaceuticals International by 77.3% in the 4th quarter. Deutsche Bank AG now owns 142,397 shares of the company's stock valued at $2,817,000 after buying an additional 62,083 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KNSA shares. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Stock Up 0.2%

KNSA traded up $0.09 during trading on Friday, reaching $37.10. The company's stock had a trading volume of 396,031 shares, compared to its average volume of 411,524. The firm has a fifty day simple moving average of $31.86 and a two-hundred day simple moving average of $27.08. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $37.34. The company has a market cap of $2.75 billion, a price-to-earnings ratio of 927.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 29,325 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the sale, the insider owned 57,403 shares in the company, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 11,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer owned 38,011 shares of the company's stock, valued at $1,324,303.24. This represents a 22.44% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 562,271 shares of company stock worth $18,716,309. Insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.